Lindis Blood Care Secures Funding for CATUVAB® Development

Lindis Blood Care GmbH has announced the successful first closing of a financing round to propel its tumor-cell-removal device, CATUVAB®, towards market readiness. The funding round was led by Brandenburg Kapital, alongside High-Tech Gründerfonds and private investors. This investment aims to prepare CATUVAB® for European market approval and launch by end of Q1 2025. The device, designed for safe autologous blood transfusions during cancer surgeries, promises a cost-effective method for removing tumor cells.

CATUVAB® integrates seamlessly into existing clinical practices, offering a promising alternative to allogeneic blood transfusions, which can cause severe side effects. Clinical study REMOVE affirmed its safety and efficiency, achieving all primary and secondary objectives with high statistical significance. With the CE Mark approval in progress and FDA submission ongoing, Lindis Blood Care anticipates significant advancements in oncological surgery protocols.